Attached files
file | filename |
---|---|
10-Q - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_10q.htm |
EX-31.1 - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_ex31-1.htm |
EX-32.2 - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_ex32-2.htm |
EX-32.1 - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_ex32-1.htm |
Exhibit
31.2
CERTIFICATION
I, Michael Hongjie Lan, certify that:
1. I have reviewed this
Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical
Company;
2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the
statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this
report;
4. The registrant’s other certifying officer(s) and I
are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a. Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed
under our supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is
being prepared;
b. Designed such internal control over
financial reporting, or caused such internal control over financial reporting to
be designed under our
supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principals;
c. Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
d. Disclosed in this report any change in
the registrant’s internal control over financial
reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of
an annual report) that has
materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial
reporting; and
5. The registrant’s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting to the
registrant’s auditors and the audit committee of
the registrant’s board of directors (or persons
performing the equivalent functions):
a. All significant deficiencies and
material weaknesses in the design or operation of internal controls over financial
reporting which are reasonably likely to adversely affect the
registrant’s ability to record, process, summarize
and report financial information; and
b. Any fraud, whether or not material, that
involves management or
other employees who have a significant role in the registrant’s internal controls over financial
reporting.
Date: May
17, 2010
|
/s/ Michael H. Lan
|
|
Michael
H. Lan
|
||
Chief Financial
Officer
|
||
(Principal
Financial and Accounting Officer)
|